State Street SPDR S&P Pharmaceuticals ETF
XPH
60 hedge funds and large institutions have $156M invested in State Street SPDR S&P Pharmaceuticals ETF in 2016 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 18 increasing their positions, 23 reducing their positions, and 13 closing their positions.
15% less funds holding
Funds holding: 71 → 60 (-11)
20.57% less ownership
Funds ownership: 52.65% → 32.08% (-21%)
22% less repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 23
40% less capital invested
Capital invested by funds: $259M → $156M (-$104M)
77% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$2.87M |
| 2 |
Mirae Asset Global Investments
Seoul,
South Korea
|
+$1.47M |
| 3 |
PVH
Psagot Value Holdings
Tel Aviv,
Israel
|
+$785K |
| 4 |
WBG
Wharton Business Group
Malvern,
Pennsylvania
|
+$218K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$203K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$82.9M |
| 2 |
Barclays
London,
United Kingdom
|
-$19M |
| 3 |
Morgan Stanley
New York
|
-$4.85M |
| 4 |
SG Americas Securities
New York
|
-$4.11M |
| 5 |
Citigroup
New York
|
-$2.13M |
XPH Hedge Fund Activity: Q2 2016 in Review
60 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in State Street SPDR S&P Pharmaceuticals ETF (XPH) for Q2 2016, worth a combined $156M — down 40% from $259M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of XPH and 3 opened new positions — a net loss of 10 holders — while 23 trimmed existing stakes and 18 added.
The largest buyer was Bank of America, adding an estimated $2.87M. The largest seller was Goldman Sachs, cutting an estimated $82.9M.
- 60 institutional investors held State Street SPDR S&P Pharmaceuticals ETF (XPH) as of Q2 2016, down from 71 in Q1 2016.
- Funds reported $156M of State Street SPDR S&P Pharmaceuticals ETF stock for Q2 2016, down 40% quarter-over-quarter.
- 3 funds opened new State Street SPDR S&P Pharmaceuticals ETF positions in Q2 2016 and 13 closed out, a net change of -10 holders.
- The largest State Street SPDR S&P Pharmaceuticals ETF buyer in Q2 2016 was Bank of America, an estimated $2.87M added.
- The largest State Street SPDR S&P Pharmaceuticals ETF seller in Q2 2016 was Goldman Sachs, an estimated $82.9M sold.
Based on aggregated 13F filings for Q2 2016.